RHEUMATOLOGY PEER REVIEWED 2021 PUBLICATIONS

1. Adams L, Lester S, Hoon E, van der Haak H, Proudman C, Hall C, et al. Patient satisfaction and acceptability with telehealth at specialist medical outpatient clinics during the COVID-19 pandemic in Australia. Intern Med J. 2021;51(7):1028-37.

2. Arnold JB, Halstead J, Grainger AJ, Keenan AM, Hill CL, Redmond AC. Foot and Leg Muscle Weakness in People With Midfoot Osteoarthritis. Arthritis Care Res (Hoboken). 2021;73(6):772-80.

3. Austin K, Dures E, Almeida C, Cramp F, Guly CM, Hill CL, et al. Patient perceptions of physical activity after a diagnosis of Giant Cell Arteritis: analysis of multinational qualitative data. Arthritis Care Res (Hoboken). 2021.

4. Bhushan V, Lester S, Briggs L, Hijjawi R, Shanahan EM, Pontifex E, et al. Real-Life Retention Rates and Reasons for Switching of Biological DMARDs in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. Front Med (Lausanne). 2021;8:708168.

5. Bruera S, Carmona L, Lopez-Olivo MA, Westrich-Robertson T, March L, Negron JB, et al. Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. Semin Arthritis Rheum. 2021;51(5):1113-6.

6. Bryant MJ, Schubert JP, Black RJ, Hill CL. Patient-Reported Experience Measures in outpatient rheumatology care: a systematic review. Rheumatol Adv Pract. 2021;5(3):rkab079.

7. Bunjo LJ, Reynolds AC, Appleton SL, Dorrian J, Vetter C, Gill TK, et al. Sleep Duration Moderates the Relationship Between Perceived Work-Life Interference and Depressive Symptoms in Australian Men and Women from the North West Adelaide Health Study. Int J Behav Med. 2021;28(1):29-38.

8. Cai G, Aitken D, Laslett LL, Hill C, Wluka AE, March L, et al. The association between change in bone marrow lesion size and change in tibiofemoral cartilage volume and knee symptoms. Rheumatology (Oxford). 2021;60(6):2791-800.

9. Davis CR, Ruediger CD, Dyer KA, Lester S, Graf SW, Kroon FPB, et al. Colchicine is not effective for reducing osteoarthritic hand pain compared to placebo: a randomised, placebo-controlled trial (COLAH). Osteoarthritis Cartilage. 2021;29(2):208-14.

10. Farquhar H, Vargas-Santos AB, Pisaniello HL, Fisher M, Hill C, Gaffo AL, et al. Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. Rheumatol Adv Pract. 2021;5(1):rkaa073.

11. Hausmann JS, Kennedy K, Simard JF, Liew JW, Sparks JA, Moni TT, et al. Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. Lancet Rheumatol. 2021;3(10):e707-e14.

12. Hill CL, Rowett D, Dartnell J. Improving the quality use of highly specialised drugs. Aust Prescr. 2021;44(5):144-5.

13. Jones B, Flurey CA, Proudman S, Ferreira RJO, Voshaar M, Hoogland W, et al. Considerations and priorities for incorporating the patient perspective on remission in rheumatoid arthritis: An OMERACT 2020 special interest group report. Semin Arthritis Rheum. 2021;51(5):1108-12.

14. Keen HI, Barrett C, Hill C. Improving knowledge and data about the medical workforce underpins healthy communities and doctors. Med J Aust. 2021.

15. Kroon FPB, van der Heijde D, Maxwell LJ, Beaton DE, Abishek A, Berenbaum F, et al. Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Semin Arthritis Rheum. 2021.

16. Lambert R, Burgess N, Hillock N, Gailer J, Hissaria P, Merlin T, et al. South Australian Medicines Evaluation Panel in review: providing evidence-based guidance on the use of high-cost medicines in the South Australian public health system. Aust Health Rev. 2021;45(2):207-13.

17. Maxwell LJ, Beaton DE, Boers M, D'Agostino MA, Conaghan PG, Grosskleg S, et al. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Semin Arthritis Rheum. 2021.

18. McClure ME, Zhu Y, Smith RM, Gopaluni S, Tieu J, Pope T, et al. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models. Rheumatology (Oxford). 2021;60(3):1491-501.

19. New-Tolley J, Reynolds AC, Appleton SL, Gill TK, Lester S, Adams RJ, et al. Sleep disorders and gout in Australian adults. BMC Rheumatol. 2021;5(1):30.

20. Pathmanathan K, Robinson PC, Hill CL, Keen HI. The prevalence of gout and hyperuricaemia in Australia: An updated systematic review. Semin Arthritis Rheum. 2021;51(1):121-8.

21. Pisaniello HL, Fisher MC, Farquhar H, Vargas-Santos AB, Hill CL, Stamp LK, et al. Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review. Arthritis Res Ther. 2021;23(1):130.

22. Rasch L, Boers M, Lems W, van Schaardenburg D, Proudman S, Hill CL, et al. Patient perspective on remission in rheumatoid arthritis: Validation of patient reported outcome instruments to measure absence of disease activity. Semin Arthritis Rheum. 2021.

23. Rischin A, Liew D, Black R, Fletcher A, Buchbinder R, Lassere M, et al. Healthcare access and attitudes towards telehealth during the early phase of the COVID-19 pandemic among an Australian cohort with inflammatory arthritis. Intern Med J. 2021;51(5):788-92.

24. Robson J, Mackie S, Hill C. Patient Reported Outcomes in Large Vessel Vasculitides. Curr Rheumatol Rep. 2021;23(2):7.

25. Robson JC, Almeida C, Dawson J, Bromhead A, Dures E, Guly C, et al. Patient perceptions of health-related quality of life in giant cell arteritis; international development of a disease-specific Patient-Reported Outcome Measure. Rheumatology (Oxford). 2021.

26. Safiri S, Kolahi AA, Cross M, Hill C, Smith E, Carson-Chahhoud K, et al. Prevalence, Deaths, and Disability-Adjusted Life Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017. Arthritis Rheumatol. 2021;73(4):702-14.

27. Sattui SE, Conway R, Putman MS, Seet AM, Gianfrancesco MA, Beins K, et al. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. Lancet Rheumatol. 2021;3(12):e855-e64.

28. Sharma C, Whittle S, Haghighi PD, Burstein F, Keen HI. Response to 'Correspondence on 'Mining social media data to investigate patient perceptions regarding DMARD pharmacotherapy for rheumatoid arthritis'' by Reuter et al. Ann Rheum Dis. 2021.

29. Stamp LK, Farquhar H, Pisaniello HL, Vargas-Santos AB, Fisher M, Mount DB, et al. Management of gout in chronic kidney disease: a G-CAN Consensus Statement on the research priorities. Nat Rev Rheumatol. 2021;17(10):633-41.

30. Stanton TR, Braithwaite FA, Butler D, Moseley GL, Hill C, Milte R, et al. The EPIPHA-KNEE trial: Explaining Pain to target unhelpful pain beliefs to Increase PHysical Activity in KNEE osteoarthritis - a protocol for a multicentre, randomised controlled trial with clinical- and cost-effectiveness analysis. BMC Musculoskelet Disord. 2021;22(1):738.

31. Takeuchi T, Rischmueller M, Blanco R, Xavier RM, Ueki Y, Atsumi T, et al. Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Mod Rheumatol. 2021;31(3):534-42.

32. Tam LS, Tanaka Y, Handa R, Li Z, Lorenzo JP, Louthrenoo W, et al. Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID-19 pandemic. Int J Rheum Dis. 2021;24(6):733-45.

33. Tieu J, Cheah JT, Black RJ, Christensen R, Ghosh N, Richards P, et al. Improving benefit-harm assessment of glucocorticoid therapy incorporating the patient perspective: The OMERACT glucocorticoid core domain set. Semin Arthritis Rheum. 2021.

34. Tieu J, Lester S, Raymond W, Keen H, Hill CL, Nossent J. Cancer in Anti-Neutrophil Cytoplasm Antibody-Associated Vasculitis and Polyarteritis Nodosa in Australia: A Population-Based Study. ACR Open Rheumatol. 2021.

35. Tieu J, Lester S, Raymond W, Keen HI, Hill CL, Nossent J. Mortality and cause of death in patients with AAV/PAN in Australia-a population-based study. Rheumatology (Oxford). 2021.

36. Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, et al. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease. Front Immunol. 2021;12:671503.

37. Venter G, Tieu J, Black R, Lester S, Leonardo N, Whittle SL, et al. Perspectives of Glucocorticoid Use in Patients with Rheumatoid Arthritis. ACR Open Rheumatol. 2021;3(4):231-8.

38. Wang Y, Jones G, Hill C, Wluka AE, Forbes AB, Tonkin A, et al. Effect of atorvastatin on knee cartilage volume in patients with symptomatic knee osteoarthritis: results from a randomised placebo-controlled trial. Arthritis Rheumatol. 2021.

39. Wang Y, Teichtahl AJ, Jones G, Keen HI, Hill CL, Wluka AE, et al. METHODS - A randomised controlled trial of METhotrexate to treat Hand Osteoarthritis with Synovitis: study protocol for a randomised controlled trial. BMC Musculoskelet Disord. 2021;22(1):953.

40. Whittle SL, Hazlewood GS, Robinson P, Johnston RV, Leder K, Glennon V, et al. COVID‐19 vaccination for people with autoimmune inflammatory rheumatic diseases on immunomodulatory therapies (protocol). Cochrane Database of Systematic Reviews. 2021(6):Art. No.: CD014991.

41. Wiese MD, Hopkins AM, King C, Wechalekar MD, Lee A, Spargo L, et al. Precision Medicine With Leflunomide: Consideration of the DHODH Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. Arthritis Care Res (Hoboken). 2021;73(7):983-9.